|
Baltimore-based T. Rowe Price said the fund and similar
portfolios for institutional clients, focused on healthcare,
medicine and life sciences, held $14.8 billion as of April 30.
That was up by $5.9 billion since the end of 2013, including
$1.8 billion of inflows.
If flows were to continue at the current pace, portfolio manager
Taymour Tamaddon said in a statement, "it could eventually
strain our ability to invest efficiently and result in a less
effective investment strategy."
Data from Thomson Reuters Lipper unit shows that healthcare and
biotech funds, with total assets of $114 billion, had net
deposits of $12 billion so far this year through May 27.
That was by far the largest inflow among all sector equity
funds. Natural resources funds were in second place with $5.7
billion of inflow in the same period.
The largest fund in the healthcare and biotech sector is the $50
billion Vanguard Health Care Fund, Lipper said.
(Reporting by Ross Kerber; Editing by Dan Grebler)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
